Petrelintide Drug Asset Due Diligence Report 2026

This Petrelintide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

The amylin thesis and Roche transaction are compelling; require competitive weight-loss, tolerability, and combination data before final commitment.

The central underwriting question is whether Petrelintide can convert its Synthetic peptide profile and AMYR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Petrelintide (query alias: petrelintide)
Modality / target	Synthetic peptide; AMYR; AMYR modulators
Highest global status	Phase 2
Originator	Zealand Pharma A/S
Active developers	Zealand Pharma A/S

The MCP disease footprint includes Diabetes Mellitus, Type 2, Obesity, Overweight. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06662539	Phase 2	Completed	493	Percent change from baseline in body weight to Week 28
NCT07589686	Phase 2	Not yet recruiting	486	Percentage Change in Body Weight between Arms 1 and 6
NCT06926842	Phase 2	Active, not recruiting	221	Percentage Change in Body Weight

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

2598-P: Long-Acting Amylin Analog Petrelintide Does Not Delay Gastric Emptying

Phase 1; n=72; evaluation: Positive. Reported fields: AE = The incidence of gastrointestinal (GI) AEs was low with OW doses; vomiting occurred in one participant, who was also the only participant to discontinue due to GI AE ; AE = The incidence of gastrointestinal (GI) AEs was low with OW doses; vomiting occurred in one participant, who was also the only participant to discontinue due to GI AE

3083-LB: Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1

Phase 2; n=485; evaluation: Positive. Reported fields: -; AE(discontinued) = 1.5 %

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

Phase 2; n=493; evaluation: Positive. Reported fields: Body weight(week 28) = resulted in statistically significant and clinically meaningful weight loss. % Met; Body weight(week 28) = resulted in statistically significant and clinically meaningful weight loss. % Met

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Petrelintide addresses Diabetes Mellitus, Type 2, Obesity, Overweight. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-03-12	Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity	Phase 2	US$1,650.0M upfront; US$3,600.0M milestones; US$5,300.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake”. The milestone feed surfaced a patent-application signal described as “Petrelintide for reducing weight whilst preserving lean mass”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Weight-loss magnitude and durability versus incretin-led standards
Gastrointestinal tolerability, discontinuation, and lean-mass profile
Commercial positioning of monotherapy versus combinations

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO